After Dr. Evans was recently announced – June 2020 – by Guardion Health Sciences ($GHSI) as the new Interim President and Interim Chief Executive Officer, it is today that A.C. Schmidt is also being welcomed to the company. He will serve as Vice President and Chief Financial Officer within the executive management team.
Why have Dr. Evans and A.C. Schmidt been brought in?
Dr. Evans was proudly announced by the Board of Directors last month as the new Interim President and Interim Chief Executive Officer of the Company. He’s the founder of the subsidiary VectorVision® and has been a member of the Board of Directors since September 2017, while being the Chief Science Officer of Guardion. It’s a special and influential position with a lot of responsibility, especially as Dr. Evans takes over the position from the company’s founder, Michael Favish.
Immediately after the announcement, Dr. Evans made clear that everyone is ready and on the same page. The necessary capital has been raised, Guardion’s balance sheet looks healthy and entering the stock market in 2019 has significantly strengthened the company’s market position. The goal is now to effectively focus on capital, improve the financial and operational performance of the business units and increase long-term shareholder value.
The company’s transition takes on colour when, under the leadership of Dr. Evans, experienced A.C. Schmidt is recruited to revitalize the team. Schmidt has over 20 years of experience in the financial management working for several listed companies operating in a variety of industries. With this background, the challenge now is to take care of the financial department, mergers, acquisitions and capital market strategies. It looks promising and Guardion is counting on sales growth and more profitability.
For those who are new here, Guardion Health Sciences in a nutshell
Guardion is a market leader in the field of eye care with a specialization in ocular health. This means that the company is engaged in the early detection, intervention and monitoring of a range of eye diseases. These are epidemic or near-epidemic profiles, for which there is significant market potential with early diagnosis and treatment. Guardion does this by combining targeted ocular nutrition with innovative evidence-based diagnostic technology. Thanks to years of expertise and scientific knowledge, Guardion has become a well-recognised company in the industry.
Guardion currently focuses in particular on patients who are at risk for vision loss related to a depleted macular pigment, particularly patients at risk for macular degeneration, patients with nerve damage in glaucoma and patients with circulatory dysfunction in the ocular vessels.
Several leading patented technologies and new treatments with a high potential
VectorVision – a wholly-owned subsidiary founded by Dr. Evans – is a supplier of standardized vision tests and a market leader in contrast sensitivity, currently the most widely used and recognized clinical contrast sensitivity test. In addition, it focuses on studies and mitigation of glare and conducts the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity tests.
In addition, great news followed from VectorVision last week. VectorVision’s CSV-2000 has received approval from the Korean Intellectual Property Office. This is the first and only computer vision test device that offers standardized contrast sensitivity testing along with the full range of visual acuity, color, astigmatism, fixation and other vision tests. In addition, the CSV-2000 is the only device with AcQviz patented technology for automatic calibration of the monitor light source. A significant breakthrough that has great potential in the eye care industry.
The company is also working on Lumega-Z, the only micronized lipid-based nutritional formula designed to restore and maintain the condition of a depleted macula pigment. This unique administration platform ensures the highest level of absorption and rapid patient response to treatment.
The Mapcat is the most repeatable and accurate measurement technology for MPOD (Macular Pigment Optical Density). Mapcat is protected by patents in the US and Europe.
Finally, with the GlaucoCetin, Guardion possess the first regulated vision-specific medical food designed to support and protect the mitochondrial function of optic nerve cells in patients with glaucoma.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.